[{"id":"ad76d4c3-113f-4c47-a241-b90088f0adad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04128085","created_at":"2021-01-18T20:09:53.991Z","updated_at":"2024-07-02T16:36:52.457Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors","source_id_and_acronym":"NCT04128085","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQB3804"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 11/15/2019","start_date":" 11/15/2019","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2019-12-16"}]